Genentech, Inc.

Medimmune Limited

F. Hoffmann-la Roche Ag

Medimmue Limited

Binqing Wei

Philip Wilson Howard

William Alexander Denny

Lewis J Gazzard

John A Flygare

Timothy Heffron

Steven T Staben

Bryan K Chan

Jun Liang

Nicole Blaquiere

Rohan V Mendonca

Stephen Colin Price

Daniel P Sutherlin

Thomas Pillow

Michael Siu

Steven Huy Do

Peter Scott Dragovich

Andrew Madin

Brian Salvatore Safina

Alan G Olivero

Eileen Mary Seward

Robert Andrew Heald

Adrian Folkes

Aleksandr Kolesnikov

Guiling Zhao

Richard A Goldsmith

Emanuela Gancia

Luke Masterson

Craig Stivala

Mark X Sliwkowski

Gordon William Rewcastle

Daniel Fred Ortwine

Chudi Obioma Ndubaku

Vishal Verma

Wendy B Young

James John Crawford

Graham Elgin Jones

Sushant Malhotra

Michael Lainchbury

Danette Dudley

Leanna Staben

Elisia Villemure

Weiru Wang

Richard Leonard Elliott

Lan Wang

Kin Chiu Fong

Naomi S Rajapaksa

Aihe Zhou

Tim Heffron

Moana Tercel

Joy Drobnick

Janet L Gunzner-Toste

Yonghan Hu

Aijun Lu

Ho Huat Lee

Matthew W Cartwright

David Favor

Andrew Good

Terry Kellar

Jennafer Dotson

Malcolm Huestis

Baihua Hu

Blake Daniels

John Tellis

Jack Sadowsky

Muriel Bonnet

Anna Giddens

Bohdan Waszkowycz

Guo-Liang Lu

Samantha Alyson Green

Robert Anthony Blake

Jianfeng Xin

Christian Miller

Neville James McLean

Edna F Choo

Sussie Lerche Krintel

Laurent Salphati

Susan Kaufman

Tracy Kleinheinz

Matthew Leo Landry

Christian Nilewski

Janet Gunzner-Toste

Neville James Mclean

Chudi Ndubaku

Brian Safina

Naomi Rajapaksa

John C Tellis

Thomas H Pillow

Adrian J Folkes

John Flygare

3-Carbonylaminoisoquinoline compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the 3-carbonylaminoisoquinoline compounds.

Isoquinoline compounds for the treatment of cancer

Isoquinoline compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the isoquinoline compounds.

Isoquinoline compounds and uses thereof

Provided herein are aza-tetracyclic oxazepinyl compounds useful in the treatment of cancers.

Aza-tetracyclic oxazepine compounds and uses thereof

Naphthyridine compounds and uses thereof

The present disclosure relates to compounds and salts thereof that are useful for inhibiting target polypeptides and proteins, in particular, bromodomain (e.g., BRD4) proteins. Also disclosed are pharmaceutical compositions comprising the compounds, or a salt (e.g., a pharmaceutically acceptable salt) thereof, and methods of using such compounds and salts in the treatment of various bromodomain-mediated diseases or disorders.

Tert-butyl (s)-2-(4-(phenyl)-6H-thieno[3, 2-f][1, 2, 4]triazolo[4, 3-a] [1,4]diazepin-6-yl) acetate derivatives and related compounds as bromodomain BRD4 inhibitors for treating cancer

This invention relates to peptidomimetic linkers and anti-body drug conjugates thereof pharmaceutical compositions containing them, and to their use in therapy for the prevention treatment of cancer.

Peptidomimetic compounds and antibody-drug conjugates thereof

The present disclosure relates to bifunctional compounds, which can be used as modulators of targeted ubiquitination. In particular, the present disclosure is directed to compounds which contain on one end a VHL ligand moiety, which binds to the VHL E3 ubiquitin ligase, and on the other end a moiety that binds a target protein such that degradation of the target protein/polypeptide is effectuated. Also disclosed are VHL ligands.

(4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof

Conjugate compounds of formula (A): wherein: where Rand Rare independently selected from H, F, Csaturated alkyl, Calkenyl, which alkyl and alkenyl groups are optionally substituted by a group selected from Calkyl amido and Calkyl ester; or, when one of Rand Ris H, the other is selected from nitrile and a Calkyl ester; 

Pyrrolobenzodiazepines and conjugates thereof

This invention relates to peptidomimetic linkers and anti-body drug conjugates thereof, pharmaceutical compositions containing them, and to their use in therapy for the prevention treatment of cancer.

Conjugate compounds of formula (A): wherein:  

Benzoxepin compounds of Formula I, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 

Benzoxepin PI3K inhibitor compounds and methods of use

Benzoxepin compounds of Formula I, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Zis CRor N; Zis CRor N; Zis CRor N; Zis CRor N; and where (i) Xis N and Xis S, (ii) Xis S and Xis N, (iii) Xis CRand Xis S, (iv) Xis S and Xis CR; (v) Xis NRand Xis N, (vi) Xis N and Xis NR, (vii) Xis CRand Xis O, (viii) Xis O and Xis CR, (ix) Xis CRand Xis C(R), (x) Xis C(R)and Xis CR; (xi) Xis N and Xis O, or (xii) Xis O and Xis N, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 

Growing community of inventors

South San Francisco, CA, United States of America

Binqing Wei